

Resource Summary Report

Generated by [RRID](#) on Aug 28, 2026

EO771

RRID:CVCL_GR23

Type: Cell Line

Proper Citation

CLS Cat# 305352, RRID:CVCL_GR23

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_GR23

Proper Citation: CLS Cat# 305352, RRID:CVCL_GR23

Description: Cell line EO771 is a Cancer cell line with a species of origin Mus musculus (Mouse)

Sex: Female

Disease: Malignant neoplasms of the mouse mammary gland

Defining Citation: [PMID:16312045](#), [PMID:24391448](#), [PMID:32699527](#), [PMID:33026171](#)

Comments: Miscellaneous: STR profile from personal communication of Rodriguez-Tarduchy Segovia, Gemma., Characteristics: Belongs to the luminal subtype B; ERalpha-, ERbeta+, PR+ and ErbB2+ (PubMed=32699527).

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: EO771

Synonyms: Eo771, E0771, EO 771

Cross References: ATCC:CRL-3461, ChEMBL-Cells:ChEMBL4483168, ChEMBL-Targets:ChEMBL4483234, CLS:305352, PubChem_Cell_line:CVCL_GR23, Wikidata:Q54832331

ID: CVCL_GR23

Vendor: CLS

Catalog Number: 305352

Record Creation Time: 20260408T073026+0000

Record Last Update: 20260816T002527+0000

Ratings and Alerts

No rating or validation information has been found for EO771.

No alerts have been found for EO771.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 463 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Leu JS, et al. (2026) Combined inhibition of S100A4 and TIGIT suppresses late-stage breast cancer metastasis. *Cancer letters*, 649, 218491.

Li W, et al. (2026) A microbiota-derived bile acid overcomes antibiotic-induced hyporesponsiveness to immune checkpoint therapy by enhancing CD8 + T cell antitumor immunity. *bioRxiv : the preprint server for biology*.

Tang XT, et al. (2026) Mapping the Tissue-of-Origins of Mesenchymal Stromal Cells in Injury Repair. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(3), e09533.

Tsuji T, et al. (2026) Microglia Display Heterogeneous Initial Responses to Disseminated Tumor Cells. *Cancer research*, 86(6), 1414.

Niravath P, et al. (2026) A Phase II Study of Docetaxel and Pembrolizumab plus Interleukin 12 Gene Therapy in Nonmetastatic, Anthracycline-Refractory Triple-Negative Breast Cancer (INTEGRAL). *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(9), 1697.

Li G, et al. (2026) Spatial Multiomics Analyses Reveal That Diabetes Promotes Pancreatic Cancer Progression by Stimulating Cholesterol-Induced Neutrophil Extracellular Trap Formation. *Cancer research*, 86(10), 2327.

Kiliti AJ, et al. (2026) An AIB1 isoform rewires glucocorticoid receptor signaling to promote TNBC progression. *iScience*, 29(2), 114768.

Zhou T, et al. (2026) Pharmacologic Modulation of ARID3A with Rimegepant Reactivates Type I Interferon Signaling and Sensitizes Triple-Negative Breast Cancer to PD-1 Blockade. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(40), e21541.

Singh D, et al. (2026) Antibody-Mediated Targeting of Secretory Protein SCUBE3 Suppresses Cancer Progression by Inhibiting Oncogenic Signaling and Inducing Antitumor Immunity. *Cancer research*, 86(5), 1252.

Young RG, et al. (2026) ACS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis. *Cancer research*, 86(14), 3502.

Chen F, et al. (2026) Hierarchical Targeting of TREM2+ Myeloid Cells via Acid-Triggered OMVs Reprogram Immunosuppression and Suppress Osteolysis in Bone-Metastatic TNBC. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(32), e17369.

McRae SW, et al. (2026) Linking tumor viability and immune infiltration with dual-nucleus MRI in preclinical models. *Npj imaging*, 4(1).

Kopp A, et al. (2026) In Vivo Auto-tuning of Antibody-Drug Conjugate Delivery to Maximize Efficacy Using High-Avidity, Low-Affinity Antibodies. *Molecular cancer therapeutics*, 25(4), 610.

Hoyt-Miggelbrink AM, et al. (2026) Upregulation of TNFR2 Precedes TOX Expression by Exhausted T cells and Restricts Antitumor and Antiviral Immunity. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(4), 782.

Alvarez-Eraso KLF, et al. (2026) Estradiol Reprograms Microglia to Create an Immune-Suppressed Niche Permissive to Breast Cancer Brain Metastasis. *bioRxiv : the preprint server for biology*.

Yu J, et al. (2026) 6-Hydroxydopamine promotes antitumor immunity through macrophage remodeling beyond sympathetic ablation. *Neuron*, 114(14), 2532.

Tong Q, et al. (2026) Detachment-Induced FAK-STAT3-NNMT Inhibits CTCs Anoikis to Promote Breast Cancer Metastasis by Enhancing Fatty Acid Oxidation. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(29), e22837.

Heard MA, et al. (2025) Genetic and pharmacological targeting of nicotinic acetylcholine receptor action blocks tumor progression in mouse models of breast cancer. *Journal of immunology* (Baltimore, Md. : 1950), 214(8), 2098.

Liang Z, et al. (2025) *Atractylodes macrocephala* Koidz. Polysaccharide Alleviates Chemotherapy-Induced Depression-Like Behaviors Through the Gut-Brain Axis. *International journal of molecular sciences*, 26(20).

Beeghly GF, et al. (2025) Large adipocytes alter mode of lipid release and promote breast cancer malignancy. *bioRxiv : the preprint server for biology*.